TMCnet News
Burzynski Research Institute, Inc. Announces Publication of Phase II Results in Adults with Recurrent Anaplastic AstrocytomaBurzynski Research Institute, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapies for patients with brain tumors and other cancers, announces the publication of data by the Burzynski Clinic on two of the company's clinical stage products Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®). Antineoplastons A10 and AS2-1 are synthetic amino acid derivatives. The phase II, single-arm, two-stage, interventional trial was conducted in the United States and evaluated adults with recurrent anaplastic astrocytoma (AA). All patients previously underwent surgery, all received radiation therapy and 59% of patients underwent chemotherapy. The study was closed for admission after enrollment of 27 adults out of a planned 40 patients, as the goal for complete and partial response had been met in five study eligible patients. Progression-free survival (PFS) and overall survival (OS) at 1, 2, 5 and 10 years are presented. The only serious, but reversible, toxicity was Grade 3 hypokalemia in 7% of patients. No chronic toxicities were noted. The publication entitled, "A Phase II Study of Antineoplastons A10 and AS2-1 Injections in Adult Patients with Recurrent Anaplastic Astrocytoma-Final report (Protocol BT (News - Alert)-15)" was published in Cancer and Clinical Oncology 2015; 4(2):13-23. About Burzynski Research Institute, Inc. Burzynski Research Institute, Inc. (OTCBB: BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to an ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150618006274/en/ |
